We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Vitamin D Repletion on Insulin Resistance

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00606957
First Posted: February 5, 2008
Last Update Posted: October 13, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rockefeller University
  Purpose

The reason for doing this study is to learn whether raising a person's vitamin D level from below normal to normal levels will improve his or her body's ability to use sugar. Vitamin D is well known to be an important vitamin for the development and maintenance of bones. Recently, scientists have learned that vitamin D may have a role in the prevention of cancer, diabetes, and autoimmune diseases. The investigators are specifically interested in studying this question in the overweight/obese population as they are at greater risk for both vitamin D deficiency and impaired ability to metabolize sugar (glucose intolerance).

Primary Hypotheses:

Vitamin D repletion (increasing the serum 25(OH)D level from ≤ 20 ng/ml to ≥ 30 ng/ml) will improve insulin sensitivity in individuals who are overweight/obese and insulin resistant.

Secondary Hypotheses:

1.Vitamin D repletion will improve biomarkers of cardiovascular risk and inflammation (directly altering macrophage cytokine production and/or indirectly as a result of improvement in insulin sensitivity.) 2.30,000 IU (0.25 mg) weekly of cholecalciferol (vitamin D3) will raise serum 25(OH)D levels from ≤ 20 ng/ml to ≥ 30 ng/ml overweight/obese population.


Condition Intervention
Obesity Dietary Supplement: Vitamin D3 (cholecalciferol)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Vitamin D Repletion on Insulin Resistance

Resource links provided by NLM:


Further study details as provided by Rockefeller University:

Primary Outcome Measures:
  • The primary outcome is change in insulin sensitivity over time, as measured by the glucose clamp, HOMA and OGTT. [ Time Frame: 14 weeks ]

Estimated Enrollment: 10
Study Start Date: January 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: Vitamin D3 (cholecalciferol)
    Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Nonsmoking men and women, ages 18-65
  • Body mass index (BMI) ≥ 28 kg/m² and within 10% of maximum weight
  • Serum 25(OH)D level ≤ 20 ng/ml
  • Serum insulin level ≥ 7.2 mU/l
  • Willingness to maintain current body weight for the duration of the study
  • Willingness to maintain baseline lifestyle activities and routines for the duration of the study
  • Willingness to avoid the use of non-steroidal anti-inflammatory drugs (NSAIDS), including low-dose daily aspirin, for at least ten days prior to each admission (due to the potential effects of these agents on inflammatory markers.)
  • Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary supplements, and herbal products during the study, with the exception of a basic multivitamin supplement.
  • If of childbearing potential, willingness to use highly effective contraception for the duration of the study.

Exclusion Criteria:

  • Current tobacco smoking
  • History of bleeding or coagulation disorders
  • Gastrointestinal disease resulting in significant gastrointestinal dysfunction or malabsorption
  • History of diabetes, or diagnosed during screening OGTT
  • Current treatment with hypertensive medications
  • History of cardiovascular disease
  • Renal disease, as evidenced by a serum creatinine above the upper limit of normal on more than one screening visit
  • History of kidney stones
  • History of chronic hepatitis, or liver enzymes (AST or ALT) more than 2.5 times the upper limit of normal
  • Primary hyperparathyroidism or baseline hypercalcemia from any cause
  • Current treatment with over-the-counter or prescription weight loss medications, such as orlistat or sibutramine
  • History of bariatric surgery
  • Current treatment with any cholesterol-lowering medications, such as statins, niacin, fibrates, or ezetimibe
  • Blood pressure ≥ 145/90 after ten minutes of rest on more than one screen visit
  • Hyperthyroidism or untreated hypothyroidism. Subjects with chronic, treated, stable hypothyroidism may be included in the study at the discretion of the Principal Investigator.
  • Pregnancy, desired pregnancy, or lactation within the study period.
  • HIV, Hepatitis B and C
  • Medical conditions requiring daily calcium supplementation or antacid use
  • Use of medications known to interact with calcium or vitamin D metabolism (bisphosphonates, corticosteroids, thiazide diuretics, cholestyramine, colestipol, mineral oil, phenytoin, barbituates, dititalis glycosides, antacids)
  • Subjects with known hypersensitivity to cholecalciferol
  • Participation in an investigational drug study within one month of screening
  • History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606957


Locations
United States, New York
Rockefeller University
New York, New York, United States, 10021
Sponsors and Collaborators
Rockefeller University
Investigators
Principal Investigator: Allegra Grossman, MD The Rockefeller University
  More Information

Responsible Party: Allegra Grossman, MD, The Rockefeller University
ClinicalTrials.gov Identifier: NCT00606957     History of Changes
Other Study ID Numbers: RUH IRB# AGR-0623
First Submitted: January 22, 2008
First Posted: February 5, 2008
Last Update Posted: October 13, 2011
Last Verified: October 2011

Keywords provided by Rockefeller University:
Obesity
Metabolism

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents